Outlook Therapeutics (OTLK) Total Non-Current Liabilities (2015 - 2026)

Outlook Therapeutics (OTLK) has 12 years of Total Non-Current Liabilities data on file, last reported at $50.2 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $50.2 million, up 8.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $50.2 million (up 8.85% YoY), and the FY2025 annual result was $46.0 million, up 7.48% from the prior year.
• Total Non-Current Liabilities grew to $50.2 million in Q1 2026 per OTLK's latest filing, from $49.2 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $54.1 million in Q1 2024 and troughed at $18.4 million in Q2 2022.
• A 5-year average of $43.2 million and a median of $46.1 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities jumped 170.81% in 2023, then retreated 14.78% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $46.9 million in 2022, then fell by 1.99% to $46.0 million in 2023, then rose by 5.44% to $48.5 million in 2024, then climbed by 1.56% to $49.2 million in 2025, then advanced by 1.9% to $50.2 million in 2026.
• Business Quant data shows OTLK's Total Non-Current Liabilities at $50.2 million in Q1 2026, $49.2 million in Q4 2025, and $46.0 million in Q3 2025.